LENZ Therapeutics, Inc. — fact timeline

LENZ Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-12 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes 24,310,915 55,181 75,972 —”

LENZ Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-12 meeting.

“Nominee Votes For Votes Withheld Broker Non-Votes Evert Schimmelpennink 20,216,637 230,219 3,995,212 Jeff George 13,462,359 6,984,497 3,995,212 Shelley Thunen 20,215,686 231,170 3,995,212”

LENZ Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $41.5 million, EPS $1.32 per share (basic and diluted).

“LENZ Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026”

LENZ Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $1.6 million.

“and Recent Corporate Highlights Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals”

LENZ Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 8, 2024, LENZ Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.”

LENZ Therapeutics, Inc.: New LENZ ceased to be a shell company upon the closing of the transactions.

“As a result of the Transactions, New LENZ ceased to be a shell company upon the Closing.”

LENZ Therapeutics, Inc.: Adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors (effective 2024-03-21).

“In connection with the Transactions, on March 21, 2024, the Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of the Company.”

LENZ Therapeutics, Inc.: Amended certificate of incorporation to effect a 1:7 reverse stock split and change company name from Graphite Bio, Inc. to LENZ Therapeutics, Inc (effective 2024-03-21).

“In connection with the Merger, the Board adopted, and the stockholders approved, an amendment to the Company’s amended and restated certificate of incorporation, to effect the Reverse Stock Split and to change the Company’s name from "Graphite Bio, Inc." to "LENZ Therapeutics, Inc." The certificate of amendment to the amended and restated certificate of incorporation was effective March 21, 2024.”

LENZ Therapeutics, Inc. underwent a change of control involving LENZ Therapeutics Operations, Inc. (closed 2024-03-21).

“On March 21, 2024, the parties to the Merger Agreement completed the Merger and the other transactions contemplated thereby in accordance with the terms of the Merger Agreement.”

Jeff George was appointed as Chair of the Board at LENZ Therapeutics, Inc..

“Also on March 21, 2024, Mr. George was appointed as the Chair of the Board.”

Zach Scheiner was appointed as Class III Director at LENZ Therapeutics, Inc..

“Zach Scheiner were appointed as Class III directors”

Evert Schimmelpennink was appointed as Class II Director at LENZ Therapeutics, Inc..

“Jeff George, Shelley Thunen, and Evert Schimmelpennink were appointed as Class II directors”

Shelley Thunen was appointed as Class II Director at LENZ Therapeutics, Inc..

“Jeff George, Shelley Thunen, and Evert Schimmelpennink were appointed as Class II directors”

Jeff George was appointed as Class II Director at LENZ Therapeutics, Inc..

“Jeff George, Shelley Thunen, and Evert Schimmelpennink were appointed as Class II directors”

James McCollum was appointed as Class I Director at LENZ Therapeutics, Inc..

“Effective as of the Effective Time, Frederic Guerard and James McCollum were appointed as Class I directors”

Frederic Guerard was appointed as Class I Director at LENZ Therapeutics, Inc..

“Effective as of the Effective Time, Frederic Guerard and James McCollum were appointed as Class I directors”

LENZ Therapeutics, Inc. shareholders approved Approval of 2024 Employee Stock Purchase Plan contingent on merger at the 2024-03-14 meeting.

“Proposal No. 4. Approval of the 2024 Employee Stock Purchase Plan, which is the combined company's 2024 Employee Stock Purchase Plan, which will become effective as of and contingent on the completion of the merger. This proposal was approved by the requisite vote of the Company's stockholders. For Against Abstain Broker Non-Votes 37,291,832 3,672,224 12,891 7,521,104”

LENZ Therapeutics, Inc. shareholders approved Approval of 2024 Equity Incentive Plan contingent on merger at the 2024-03-14 meeting.

“Proposal No. 3. Approval of the 2024 Equity Incentive Plan, which is the combined company's 2024 Equity Incentive Plan, which will become effective as of and contingent on the completion of the merger. This proposal was approved by the requisite vote of the Company's stockholders. For Against Abstain Broker Non-Votes 36,564,189 4,398,998 13,760 7,521,104”

LENZ Therapeutics, Inc. shareholders approved Approval of amendment to certificate of incorporation to effect reverse stock split and change name at the 2024-03-14 meeting.

“Proposal No. 2. Approval of an amendment to Graphite's certificate of incorporation (the "Graphite charter") to (i) effect a reverse stock split of Graphite's issued common stock at a ratio in the range between 1:6 and 1:12, inclusive, with the final ratio and effectiveness of all other ratios of such amendment and the abandonment of such amendment to be mutually agreed by the board of directors of Graphite and the board of directors of LENZ prior to the effective time and (ii) change Graphite's name to "LENZ Therapeutics, Inc.", effective as of the effective time under the Merger Agreement. This proposal was approved by the requisite vote of the Company's stockholders. For Against Abstain Broker Non-Votes 48,324,362 169,990 3,699 0”

LENZ Therapeutics, Inc. shareholders approved Approval of issuance of shares, change of control, and PIPE issuance at the 2024-03-14 meeting.

“Proposal No. 1. Approval of (i) the issuance of shares of Graphite common stock, which will represent more than 20% of the shares of Graphite common stock outstanding immediately prior to the Merger, to stockholders of LENZ pursuant to the terms of the Merger Agreement and pursuant to Nasdaq Listing Rule 5635(a), (ii) the change of control of Graphite resulting from the Merger pursuant to Nasdaq Listing Rule 5635(b), and (iii) the issuance of shares of Graphite common stock to the PIPE investors pursuant to Nasdaq Listing Rule 5635(d), which shares of Graphite common stock will represent more than 20% of the shares of Graphite common stock outstanding as of the date of the execution of the Subscription Agreement, dated as of November 14, 2023, by and among Graphite and the PIPE investors named therein. This proposal was approved by the requisite vote of the Company's stockholders. For Against Abstain Broker Non-Votes 40,937,960 37,089 1,898 7,521,104”

LENZ Therapeutics, Inc. entered into Agreement and Plan of Merger with Lenz Therapeutics, Inc. valued at 65% ownership post-merger for LENZ stockholders (effective 2023-11-14).

“On November 14, 2023, Graphite Bio, Inc., a Delaware corporation (“Graphite”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and between Graphite, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Graphite (“Merger Sub”), and Lenz Therapeutics, Inc., a Delaware corporation (“LENZ”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into LENZ (the “Merger”), with LENZ continuing as a wholly owned subsidiary of Graphite and the surviving corporation of the merger.”

LENZ Therapeutics, Inc. terminated Lease with Bayside Area Development, LLC valued at approximately $20,776,078 (effective 2023-10-26).

“The Lease Amendment provides that the Master Lease will terminate on December 31, 2024, and that the Landlord may further accelerate the termination date for the premises not subject to the Sublease by delivering written notice and paying the Company $20,000 per month for each month of further acceleration.”

LENZ Therapeutics, Inc. amended First Amendment to Lease with Bayside Area Development, LLC valued at $15,928,490 (effective 2023-10-26).

“On the Effective Date, the Company also entered into a First Amendment to Lease with the Landlord (the “Lease Amendment”) to adjust the timeline for certain payments under the Master Lease and to effect the acceleration of the termination date of the Master Lease.”

LENZ Therapeutics, Inc. entered into Sublease with Soleil Labs, LLC valued at $183,044.10 per month for the first twelve months and $189,450.64 per month for the remainder of the (effective 2023-10-26).

“On October 26, 2023 (the “Effective Date”), Graphite Bio, Inc. (the “Company”) entered into a sublease agreement (the “Sublease”) with Soleil Labs, LLC (“Tenant”) for certain premises constituting approximately 32,113 square feet of space in the building located at 233 E. Grand Avenue, South San Francisco, California (the “Premises”).”

Josh Lehrer departed as President, Chief Executive Officer at LENZ Therapeutics, Inc..

“effective as of August 21, 2023 (the “Termination Date”), Josh Lehrer, M.D., the former President, Chief Executive Officer and member of the Board of Directors of Graphite Bio, Inc. (the “Company”), separated from his employment and all officer and director positions with the Company.”

LENZ Therapeutics, Inc. announced a restructuring with charges of approximately $1.6 million (approximately 70%).

“alternatives. Under the Plan, the Company is reducing its workforce by approximately 70%. The Company expects to incur estimated severance and related costs of approximately $1.6 million, which will be recorded primarily in the third quarter of 2023. As the Plan is implemented, the Company’s management will re-evaluate the estimated costs and expenses set forth”

Kimberlee C. Drapkin was appointed as director at LENZ Therapeutics, Inc..

“On July 28, 2023, the Board of Directors (the “Board”) of Graphite Bio, Inc. (the “Company”) increased the size of the Board from ten to eleven members and appointed Kimberlee C. Drapkin as a director of the Company, effective immediately”

LENZ Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm Deloitte & Touche LLP at the 2023-07-19 meeting.

“Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023.”

LENZ Therapeutics, Inc. shareholders approved Election of the three director nominees to the Board as Class II directors to hold office until the 2026 Annual Meeting at the 2023-07-19 meeting.

“Proposal 1 - Election of Directors The Company’s stockholders elected the three (3) director nominees below to the Company’s Board of Directors as Class II directors to hold office until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.”

Josh Lehrer was appointed as Principal Financial Officer and Principal Accounting Officer at LENZ Therapeutics, Inc..

“The Company intends to appoint Josh Lehrer, the Company’s Chief Executive Officer, to serve as the Company’s Principal Financial Officer and Principal Accounting Officer effective immediately following Ms. Young’s departure.”

Alethia Young resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at LENZ Therapeutics, Inc..

“On June 19, 2023, Alethia Young, the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of Graphite Bio, Inc. (the “Company”), notified the Company of her decision to resign, effective at the close of business on June 30, 2023.”

LENZ Therapeutics, Inc. reported Fourth quarter and fiscal year 2022 results: net income Net loss was $24.6 million for the fourth quarter of 2022; Net loss was $101.1 million for fiscal year 2022, EPS $0.44 per basic and diluted share for the fourth quarter of 2022; $1.84 per basic and diluted share for fiscal year 2022.

“Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results”

LENZ Therapeutics, Inc. announced a restructuring with charges of approximately $4.9 million (approximately 50%).

“Under the Plan, the Company is reducing its workforce by approximately 50%. The Company expects to incur estimated severance and related costs of approximately $4.9 million, which will be recorded primarily in the second quarter of 2023.”

LENZ Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $24.7 million, or $0.45 per basic and diluted share, EPS $0.45 per basic and diluted share.

“Graphite Bio, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.”

Philip P. Gutry resigned as principal financial officer and principal accounting officer at LENZ Therapeutics, Inc..

“Effective as of April 1, 2022, Philip P. Gutry, who is currently serving as Chief Business Officer, Head of Finance & Investor Relations, principal financial officer and principal accounting officer of the Company, will resign from his positions as the Company’s Head of Finance & Investor Relations, principal financial officer and principal accounting officer and will continue to serve as Chief Business Officer.”

Alethia Young was appointed as Chief Financial Officer at LENZ Therapeutics, Inc..

“On March 2, 2022, Graphite Bio, Inc. (the “Company”) announced the hiring and appointment of Alethia Young as Chief Financial Officer.”

Katherine V. Stultz departed as Chief Operating Officer at LENZ Therapeutics, Inc..

“On December 6, 2021, Graphite Bio, Inc. (the “Company”) and Katherine V. Stultz, the Company’s Chief Operating Officer, agreed that Ms. Stultz’s employment with the Company will end effective as of the close of business on December 31, 2021.”